四次联手阿斯利康,和铂医药的底牌是什么?

药渡
Dec 06

11月24日,和铂医药宣布更新并深化其与阿斯利康于2025年3月达成的全球战略合作。根据最新协议,双方将整合各自技术优势,共同研发抗体偶联药物(ADC)和T细胞衔接器(TCE)等新一代生物疗法,进一步拓展在肿瘤与自身免疫性疾病领域的创新布局。来源于和铂医药官网这一合作,不仅展现和铂医药从“BD之王”到“药物基建师”的转变,更彰显了中国生物医药企业以技术平台驱动国际合作的创新范式。从项目授权到生态...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10